Anthrogenesis Corporation

Becton Dickinson and Company Limited

Celularity Inc.

Clarity Acquisition Ii LLC

Mohammad A Heidaran

Andrew L Zeitlin

Xiaokui Zhang

Vanessa R Voskinarian-Berse

Lin Kang

Andrea Liebmann-Vinson

Robert J Hariri

Ajai Pal

James W Edinger

Richard David Guarino

Catherine A Spargo

Bryce Chaney

Wolfgang Hofgartner

Robert L Campbell

Qian Ye

Jia-Lun Wang

Perry D Haaland

Eric Law

Neerav Dilip Padliya

Bhavani Stout

Stephen Jasko

Jamie H Wilkins

John Jacob Hemperly

Kristen S Labazzo

Sascha Dawn Abramson

Colleen Delaney

Shmuel Yaccoby

Andy Zeitlin

Marian Guelakis

Stewart Ernest Abbott

Ruiling Xu

Keith DeLuca

Colleen Suzanne Dulaney

Vanessa Voskinarian-berse

Vanessa Voskinarian-Berse

Vanessa A Voskinarian-Berse

Henry Rendon Barrigan

Steven Jasko

Kristine Erikson Johnson

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.

Composition for collecting and preserving placental stem cells and methods of using the composition

Composition for collecting placental stem cells and methods of using the composition

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

Methods of generating natural killer cells

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.

Method of producing erythrocytes

Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.

Methods and compositions for treatment of bone defects with placental cell populations

The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

Co-culture of placental stem cells and stem cells from a second source

The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.

Production of oligodendrocytes from placenta-derived stem cells

The invention provides populations of expanded CD34-expressing cells and methods of use. Particular embodiments provide for defined culture media useful for growing these cells, and grafts comprising these cells. The invention finds use in methods for reconstituting, repairing, and regenerating tissue damage.

Material and methods for the growth of hematopoietic stem cells

The present invention relates to cell adhesion promoting ('CAP') peptide combinations that promote cell attachment or cell adhesion to culture surfaces that are otherwise cell adhesion resistant 'CAR'. The invention provides combination of peptides that, when covalently coupled to a CAR layer such as hyaluronic acid that has been created on a polystyrene surface, promote cell attachment, growth differentiation, and execution of other desired cellular functions in culture.

Peptides for enhanced cell attachment and growth

The present invention provides specific peptides identified as having cell adhesion, growth, expression or secretion-enhancing activities. Many of the peptides of the invention may be produced in large quantity by such means as chemical synthesis or recombinant DNA methodology. They may be non-specifically adsorbed, or chemically attached to a surface or, alternatively, formulated in a culture medium to produce the desired effect on cultured cells.

Peptides promoting cell adherence, growth and secretion

Growing community of inventors

Cary, NC, United States of America

Mohammad A Heidaran